AMNEAL PHARMACEUTICALS, INC. Capital Expenditures
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Capital Expenditures of $38.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $30.70M, a 34.46% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $8.18M, a 37.89% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $21.77M, a 43.67% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $12.30M, a 27.42% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $70.06M, a 34.93% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $51.92M, a 20.15% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $43.22M, a 6.88% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $46.41M, a 2.77% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $38.87M 10-Q · filed 2026-08-06 | $60.65M derived: sum of 3 quarters · filed 2026-08-06 | $72.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.18M 10-Q · filed 2026-05-07 | $29.95M derived: sum of 2 quarters · filed 2026-05-07 | $42.25M derived: sum of 3 quarters · filed 2026-05-07 | $65.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $34.07M derived: sum of 2 quarters · filed 2026-02-27 | $56.90M derived: sum of 3 quarters · filed 2026-08-06 | $70.06M 10-K · filed 2026-02-27 |
| 2025-09-30 | $12.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $35.13M derived: sum of 2 quarters · filed 2026-08-06 | $48.29M 10-Q · filed 2025-11-06 | $63.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $22.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $35.99M 10-Q · filed 2026-08-06 | $51.15M derived: sum of 3 quarters · filed 2026-08-06 | $68.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $13.16M 10-Q · filed 2026-05-07 | $28.32M derived: sum of 2 quarters · filed 2026-05-07 | $45.26M derived: sum of 3 quarters · filed 2026-05-07 | $55.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $32.10M derived: sum of 2 quarters · filed 2026-02-27 | $42.73M derived: sum of 3 quarters · filed 2026-02-27 | $51.92M 10-K · filed 2026-02-27 |
| 2024-09-30 | $16.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $27.57M derived: sum of 2 quarters · filed 2025-11-06 | $36.77M 10-Q · filed 2025-11-06 | $46.63M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $10.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $19.82M 10-Q · filed 2025-08-07 | $29.69M derived: sum of 3 quarters · filed 2026-02-27 | $41.35M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $9.20M 10-Q · filed 2025-05-07 | $19.06M derived: sum of 2 quarters · filed 2026-02-27 | $30.72M derived: sum of 3 quarters · filed 2026-02-27 | $42.73M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $21.52M derived: sum of 2 quarters · filed 2026-02-27 | $33.53M derived: sum of 3 quarters · filed 2026-02-27 | $43.22M 10-K · filed 2026-02-27 |
| 2023-09-30 | $11.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $23.66M derived: sum of 2 quarters · filed 2024-11-12 | $33.35M 10-Q · filed 2024-11-12 | $44.82M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $21.69M 10-Q · filed 2024-08-09 | $33.16M derived: sum of 3 quarters · filed 2025-02-28 | $52.26M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $9.69M 10-Q · filed 2024-05-08 | $21.15M derived: sum of 2 quarters · filed 2025-02-28 | $40.25M derived: sum of 3 quarters · filed 2025-02-28 | $45.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $11.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $30.57M derived: sum of 2 quarters · filed 2025-02-28 | $35.61M derived: sum of 3 quarters · filed 2025-02-28 | $46.41M 10-K · filed 2025-02-28 |
| 2022-09-30 | $19.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $24.15M derived: sum of 2 quarters · filed 2023-11-09 | $34.94M 10-Q · filed 2023-11-09 | $52.44M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $15.84M 10-Q · filed 2023-08-08 | $33.34M derived: sum of 3 quarters · filed 2024-03-14 | $43.98M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $10.79M 10-Q · filed 2023-05-09 | $28.29M derived: sum of 2 quarters · filed 2024-03-14 | $38.94M derived: sum of 3 quarters · filed 2024-03-14 | $46.74M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $28.14M derived: sum of 2 quarters · filed 2024-03-14 | $35.95M derived: sum of 3 quarters · filed 2024-03-14 | $47.73M 10-K · filed 2024-03-14 |
| 2021-09-30 | $10.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $18.45M derived: sum of 2 quarters · filed 2022-11-07 | $30.23M 10-Q · filed 2022-11-07 | $59.76M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $7.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $19.59M 10-Q · filed 2022-08-08 | $49.12M derived: sum of 3 quarters · filed 2023-03-03 | $60.11M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $11.78M 10-Q · filed 2022-05-06 | $41.31M derived: sum of 2 quarters · filed 2023-03-03 | $52.30M derived: sum of 3 quarters · filed 2023-03-03 | $60.85M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $29.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $40.53M derived: sum of 2 quarters · filed 2023-03-03 | $49.08M derived: sum of 3 quarters · filed 2023-03-03 | $56.45M 10-K · filed 2023-03-03 |
| 2020-09-30 | $10.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $19.55M derived: sum of 2 quarters · filed 2021-11-08 | $26.91M 10-Q · filed 2021-11-08 | $31.43M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $8.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $15.92M 10-Q · filed 2021-08-09 | $20.44M derived: sum of 3 quarters · filed 2022-03-01 | $33.47M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $7.37M 10-Q · filed 2021-05-07 | $11.88M derived: sum of 2 quarters · filed 2022-03-01 | $24.92M derived: sum of 3 quarters · filed 2022-03-01 | $36.56M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $17.55M derived: sum of 2 quarters · filed 2022-03-01 | $29.19M derived: sum of 3 quarters · filed 2022-03-01 | $47.18M 10-K · filed 2022-03-01 |
| 2019-09-30 | $13.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $24.68M derived: sum of 2 quarters · filed 2020-11-06 | $42.66M 10-Q · filed 2020-11-06 | $62.69M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $11.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $29.63M 10-Q · filed 2020-08-06 | $49.65M derived: sum of 3 quarters · filed 2021-03-01 | $76.12M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $17.99M 10-Q · filed 2020-05-11 | $38.01M derived: sum of 2 quarters · filed 2021-03-01 | $64.48M derived: sum of 3 quarters · filed 2021-03-01 | $81.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $20.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $46.49M derived: sum of 2 quarters · filed 2021-03-01 | $63.59M derived: sum of 3 quarters · filed 2021-03-01 | $83.09M 10-K · filed 2021-03-01 |
| 2018-09-30 | $26.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $43.57M derived: sum of 2 quarters · filed 2019-11-07 | $63.06M 10-Q · filed 2019-11-07 | $87.68M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $17.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $36.60M 10-Q · filed 2019-08-05 | $61.22M derived: sum of 3 quarters · filed 2020-03-02 | $76.76M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $19.50M 10-Q · filed 2019-05-09 | $44.12M derived: sum of 2 quarters · filed 2020-03-02 | $59.66M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $24.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $40.16M derived: sum of 2 quarters · filed 2020-03-02 | $94.77M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $15.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $70.15M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $54.61M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $122.76M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |